SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK reported Q2 2026 core results with total sales of £8.4 billion (+5%…

GSK plc · 6-K filed Jul 28, 2026 at 12:50 ET

At the news

MIXEDIMPACT 6/10

6-K filed Jul 28, 2026 at 12:50 ET

GSK reported Q2 2026 core results with total sales of £8.4 billion (+5% CER) and core EPS of 50.5p (+9% CER), driven by strong Specialty Medicines and Vaccines growth. However, total operating profit plunged 75% to £481 million due to £1.9 billion in impairments, primarily from the failed camlipixant trial, and higher contingent consideration charges. The company reaffirmed 2026 guidance at the upper half of the 3-5% turnover growth range and announced a new 'Accelerate Growth' restructuring program targeting £1.9 billion in annual savings by 2029, alongside the recently closed $10.6 billion Nuvalent acquisition.

  • Q2 2026 total sales £8.4 billion, +5% CER; Core operating profit £2.8 billion, +7% CER.
  • Total operating profit fell 75% to £481 million, driven by £1.9 billion in impairments (camlipixant £1.3B, Alector £371M).
  • Core EPS rose 9% to 50.5p; Total EPS fell 69% to 10.8p.
  • 2026 guidance reaffirmed: turnover +3-5% (upper half), Core OP +7-9% (upper half), Core EPS +7-9% (lower half).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access